Ahmed Uzair, Jones Hannah, Adams Clive E
Parkside Lodge, Leeds PFT, Leeds, UK, LS12 2AE.
Cochrane Database Syst Rev. 2010 Apr 14(4):CD007445. doi: 10.1002/14651858.CD007445.pub2.
Agitated or violent behaviour constitutes 10% of all emergency psychiatric treatment. Some guidelines do not recommend the use of chlorpromazine for rapid tranquillisation but it is still often used for this purpose.
To examine the effects of oral or intramuscular chlorpromazine for psychosis induced agitation or aggression.
We searched the Cochrane Schizophrenia Group Trials Register (up to July 2009) which is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO.
Randomised control trials or double blind trials (implying randomisation) comparing chlorpromazine with another drug or placebo for people who are thought to be acutely aggressive or agitated due to psychotic illness.
We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a fixed-effects model.
One study (total n=30) met the inclusion criteria. When compared with haloperidol (Man 1973) (1 RCT, n=30) people allocated chlorpromazine were no more likely to have one additional injection than those allocated haloperidol (RR 3.00 CI 0.13 to 68.26). This remained true for 2-4 injections (RR 0.90 CI 0.52 to 1.55) and for 5 or more injections (RR 0.75 CI 0.20 to 2.79). Two people allocated chlorpromazine had sudden, serious hypotension while no one allocated haloperidol had such an effect (RR 5.00 CI 0.26 to 96.13). No extrapyramidal symptoms were observed. One person allocated chlorpromazine developed status epilepticus (RR 3.00 CI 0.13 to 68.26).
AUTHORS' CONCLUSIONS: Overall the quality of evidence is limited, poor and dated. Where drugs that have been better evaluated are available, it may be best to avoid use of chlorpromazine. Where chlorpromazine is used for acute aggression or where choices are limited, relevant trials are possible and urgently needed.
躁动或暴力行为占所有急诊精神科治疗案例的10%。一些指南不推荐使用氯丙嗪进行快速镇静,但它仍常被用于此目的。
研究口服或肌内注射氯丙嗪对精神病性激越或攻击行为的影响。
我们检索了Cochrane精神分裂症研究组试验注册库(截至2009年7月),该注册库基于对CINAHL、EMBASE、MEDLINE和PsycINFO的定期检索。
随机对照试验或双盲试验(意味着随机分组),比较氯丙嗪与另一种药物或安慰剂对因精神病性疾病而被认为有急性攻击或激越行为的患者的效果。
我们独立提取数据。对于二分数据,我们基于固定效应模型,在意向性分析的基础上计算相对风险(RR)及其95%置信区间(CI)。
一项研究(共30例)符合纳入标准。与氟哌啶醇相比(曼恩,1973年)(1项随机对照试验,30例),分配到氯丙嗪组的患者比分配到氟哌啶醇组的患者多接受一次注射的可能性并无差异(RR 3.00,CI 0.13至68.26)。在接受2 - 4次注射时也是如此(RR 0.90,CI 0.52至1.55),接受5次或更多次注射时同样如此(RR 0.75,CI 0.20至2.79)。分配到氯丙嗪组的两名患者出现了突然的严重低血压,而分配到氟哌啶醇组的患者无人出现这种情况(RR 5.00,CI 0.26至96.13)。未观察到锥体外系症状。分配到氯丙嗪组的一名患者发生了癫痫持续状态(RR 3.00,CI 0.13至68.26)。
总体而言,证据质量有限、不佳且陈旧。在有经过更好评估的药物可用的情况下,最好避免使用氯丙嗪。在使用氯丙嗪治疗急性攻击行为或选择有限的情况下,可能且迫切需要进行相关试验。